HMB-002 — Interim data
Sep 2026–Apr 2027
The Company expects to report additional data from the trial in late 2026 or early 2027.Source filing
COAG biotech catalysts & pipeline
HEMAB THERAPEUTICS HOLDINGS INC · Data as of 2026-09-08
Upcoming catalysts
sutacimig — Topline data
Sep 2026–Apr 2027
The Company expects to report data from the ongoing Phase 2 trial in late 2026 or early 2027.Source filing
HMB-003 — Initial data
mid-2027
The Company plans to initiate first-in-human studies in the second half of 2026 with initial clinical data mid-2027.Source filing